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Abstract
There is a need for an alternative to human donor corneas as the availability of good-quality tissues remains limited, with this situation 
potentially worsening as the population in many countries is progressively ageing. There have been numerous attempts to develop 
corneal equivalent as alternatives to donated human corneas as well as prostheses. In this short review, we focus on the efforts in 
bioengineering implants that promote regeneration by Canadian researchers, including our current team of authors. The examples of 
technologies developed that we describe include biomaterials that allow for partial regeneration of corneal tissue, self-assembled cornea 
constructs and cell-free corneal implants that promoted regeneration when evaluated in clinical trials in Europe. 
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The human cornea is the optically clear window of the eye and its main 
refractive component that focuses light to the retina allowing vision. 
Thus, the optical transparency of the cornea is critical for optimal 
vision. Injury or diseases that cause irreversible loss of transparency 
lead to vision loss and eventually blindness. Globally, it is estimated 
that 4.9 million individuals have bilateral corneal blindness1 while 
23 million are estimated to be unilaterally cornea blind.2 Cornea 
transplantation with human donor corneas is the only extensively 
accepted treatment to restore eyesight. In fact, human cornea is one 
of the most transplanted tissues worldwide, with more than 53,000 
corneal grafts performed in 2013 in North America alone.3 However, it 
is becoming increasingly difficult for Eye Banks worldwide to meet the 
growing demand for good-quality donated corneas, which is in part 
due to population ageing. According to the Eye Bank Association, of 
America, the number of corneal transplantations performed in the US 
has increased by 50.9 % since 2005, a number that has increased faster 
than the number of potential donors.3,4 Thus, donor tissue shortage has 
become a growing concern for most countries.5–8 
 
Artificial corneas made from traditional plastics, such as the AlphaCor® 
Keratoprosthesis are available, but these do not completely biointegrate 
into the host cornea. The Boston Keratoprostheses and osteo-odonto-
keratoprosthesis (OOKP) have a plastic optic but a corneal rim or 
tooth as the interface with the patient’s remaining cornea. These 
two biological interfaced devices have been reported to be among 
the most successful prostheses, but are still reserved for end-stage 
disease,9,10 as they restore only minimal function and require lifetime 
antibiotic therapy and immune suppression. They also increase the risk 
of other sight-threatening conditions, such as glaucoma, which require 
an additional surgical procedure, such as the placement of a shunt to 
alleviate eye pressure.
Currently, when a cornea requires replacement by transplantation, the 
pathological tissue is surgically removed and replaced by a donated 
human eye bank cornea that is sutured or glued in place. The overall 
success rate is high in many countries, such as Sweden, with rejection 
at only 10–15 % over the first 2 years post-operative. What is not as 
commonly reported is that transplantation results are still suboptimal. 
For example, immune rejection is problematic in some cases and can 
lead to graft failure. Appositioning of the graft tissue could result in 
astigmatism if the fit is not precise. Sutures are often left on for up to 
1   year as graft integration is slow, and these can become loose and 
cause infection. For high-risk patients with inflammation and severe 
pathologies (e.g. chemical burns, autoimmune diseases, previously 
rejected grafts, limbal keratoplasties), complications and failure rates 
have been as high as 49 %.11–13 Multiple surgeries are often needed and 
patients face the prospect of complete vision loss as each subsequent 
transplant fails.
Bioengineered Substitutes as  
Cornea Replacements
While corneal surgeons have practically reached a plateau for 
optimising outcomes following traditional corneal transplantation 
using human donor corneas, biomaterials technology potential offers 
a range of new opportunities for solving current limitations, as new 
materials and designs are possible. Other potential advantages that 
bioengineered corneal substitutes might have over donated human 
corneas include the following: 
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Large-scale production of biosynthetic implants offers a powerful 
potential solution to the severe shortage of human donor 
corneas worldwide: 
1. Good manufacturing practices (GMPs) eliminate the need for 
expensive screening for diseases transmitted by donors and 
for tissue quality assessment; 
2. Acellular (cell-free), corneal substitutes circumvent immune 
rejection induced by allogeneic cells, thus reducing the risk of 
graft failure and eliminating the need for chronic post-operative 
immunosuppression; 
3. The 3D shape of the corneal substitute can be tailored the same 
way contact lenses and intraocular lenses are shaped, aiming at 
more successful post-operative refractive results. Corneal shape 
is of primary importance, as it determines most of the eye’s total 
refractive power and, hence, visual acuity;14 
4. The biomechanical properties of the material can be adapted 
to the clinical need, e.g. they can be made softer, more elastic 
or stronger and firmer, or they can allow for transportation of 
fluid and solids and therefore not affect intraocular pressure 
measurements; and 
5. These biomaterials can be designed to specifically interact with 
cells, micro-organisms or molecules by the release of bioactives. 
We and others have reviewed the various keratoprostheses and 
bioengineered corneal substitutes that have been developed as 
replacements for pathological corneas and/or to promote regeneration. 
In this article, we review only the contributions of Canadian researchers 
to the development of technologies for promoting corneal regeneration 
as an alternative to donor transplantation. One of these bioengineered 
corneal implants reached clinical evaluation in Europe, in a clinical trial 
conducted in Sweden.
Keratoprostheses with Regenerative 
Capability
The traditional keratoprostheses as mentioned above have focused 
on replacement of minimal function to allow vision. Sheardown and 
co-workers have focused on keratoprostheses that have allowed 
partial regeneration, by modification of biomaterials with cell adhesion 
peptides and growth factors.15,16 The following are examples of 
biomaterials developed for use as keratoprostheses.
In Aucoin et al.,17 poly(dimethyl siloxane) (PDMS) surfaces were 
modified by covalent attachment of combinations of cell adhesion 
peptides that were derived from laminin and fibronectin. The peptides 
studied included the commonly studied YIGSR and its synergistic 
peptide PDSGR from laminin, and fibronectin-derived RGDS and PHSRN. 
Statistical analysis of the experimental adhesion results suggested 
that the concentrations of YIGSR, RGDS and PHSRN used, as well as 
the synergistic effect of YIGSR and PDSGR, had significant effects on 
cell attachment and proliferation. The use of surface modification with 
multiple peptides resulted in superior adhesion and proliferation of 
corneal epithelial cells over surfaces modified with single peptides 
only. These results showed that the use of combinations of synergistic 
peptides potentially results in enhanced cell surface interactions.
In Liu and Sheardown,18 the high water permeability of hydrogels, 
modelled with poly (N-isopropyl acrylamide), was combined with 
the high oxygen permeability of poly dimethyl siloxane (silicone) 
in an interpenetrating network (IPN). The resulting IPN possessed 
mechanical strength that was superior to that of each individual 
polymer. Incorporation of interfacial agents resulted in better 
transparency than that of the individual polymers and, overall, these 
materials demonstrated adequate corneal epithelial cell compatibility. 
While promising, there has been limited testing with these materials 
under in vivo conditions.
Self-assembled Corneal Constructs
The team of Auger, Germain and their co-workers at the Laboratoire 
D’Organogénèse Expérimentale (LOEX) have developed a fundamental 
technique for developing self-assembly of tissues by inducing 
cultured target cells to synthesise their own extracellular matrix 
(ECM). For corneal constructs, ascorbic acid was used to stimulate 
the production of collagen and other ECM molecules by cultured 
stromal cells. Sheets of secreted ECM can be stacked together to form 
a thicker stack and an epithelium is seeded on top. The morphology 
and function of these sheets reproduces many of the main features 
of the human cornea.19
Figure 1: Slit Lamp Biomicroscopy Images of 
the Corneas of All 10 Patients at 4 years after 
Grafting with a Biosynthetic Implant
Reproduced with permission from Fagerholm et al., 2014.23
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To date, self-assembled cornea constructs have been developed 
that reproduce one or more layers of the human cornea.20,21 A tissue-
engineered stroma replacement was tested in cats recently and 
at 4 months post-operation, all grafts were stable and clear.21 These 
implants were re-innervated, showing comparable touch sensitivity 
to pre-operation levels. Histological evaluation showed a lamellar 
structure similar to that of a healthy cornea.
First Demonstration of Regeneration of the 
Human Cornea Promoted by a Cell-free Implant
Members of our team recently published the 4-year follow-up results 
of a phase I clinical study where transparent biosynthetic analogues 
of human corneal stromal extracellular matrices, comprising 
carbodiimide-crosslinked recombinant human collagen type III 
(RHCIII), were implanted in the first 10 human patients.22 We showed 
that the implants were stably integrated without immunosuppression. 
Unlike donor corneas, they did not attract antigen-presenting 
dendritic cells (see Figure 1). Furthermore, by mimicking the corneal 
ECM, they promoted in-growth of the patients’ own corneal epithelial 
cells, nerves and stromal keratocytes to regenerate a neo-cornea 
(see Figure 2).22,23 This was a major step in corneal transplantation as 
we demonstrated for the first time that the human cornea is capable 
of regeneration, and that biomaterials can be used to stimulate the 
regeneration as an alternative to donor human allografts, giving hope 
to patients who were not transplanted due to a severe worldwide 
shortage of donor tissues.
Further development of these implants included the use of riboflavin 
and UVA light to potentially crosslink or weld the implants into 
the corneas of hosts. In a study conducted by Wand et al.,24 RHCIII 
corneal implants were successfully crosslinked into excised porcine 
and rabbit eyes. While further optimisation is required to address 
shrinkage that was noted after crosslinking, nevertheless, in the 
future, this technique could help reduce suture-related complications, 
Figure 2: Corneal Features in a Healthy, 
Unoperated Subject, Alongside those of 
Operated Patients, at 24 Months after 
Implantation of a Biosynthetic Cornea or a 
Human Donor Cornea 
Figure 3: Corneas of All Three Patients Before  
and After Implantation with Tectonic Grafts of 
RHCIII-MPC
(Top row) Anterior segment optical coherence tomography (ASOCT) images of a healthy 
cornea, biosynthetic implant and human donor transplant by penetrating keratoplasty 
(PK). Areas of wound-healing activity exhibit high reflectivity (white areas). (A to O) in 
vivo confocal microscopy (IVCM) images. Intact epithelium of the unoperated cornea (A), 
regenerated corneal epithelial cells on the implant surface (B) and regenerated epithelium 
of the penetrating graft (C). Regenerated nerves (E) at the subbasal epithelium in an 
implanted cornea were parallel and morphologically similar to the normal cornea (D), 
whereas regenerated subbasal nerves were also observed in a cornea transplanted with 
human donor tissue (F). Anterior stromal cell (keratocyte) nuclei (G to I) and posterior 
keratocytes (J to L) were present, with varying density, in all corneas. The endothelium (M 
to O) in all corneas exhibited a characteristic mosaic pattern. Scale bars, 2 mm (ASOCT), 
100 mm (IVCM). Reproduced with permission from Fagerholm et al., 2010.22
Patient 1’s cornea had an ulcer overlying a vascularised stroma. The green fluorescein 
staining delineates the large area of eroded epithelium. At 12 months post-operation, 
the cornea is intact and relatively clear. Patient 2 had a failed 8.5 mm diameter graft with 
a persistent ulcer and dense stromal opacification in the visual zone prior to surgery. 
A small 4 mm implant was grafted into the ulcerated area of the failed graft (arrowhead) 
and has remained relatively clear after 12 months. Patient 3 had an opacity with an 
unstable epithelial surface and vascularised stroma prior to surgery. At 9 months post-
operation, while the implant remained clear, the ingrowing conjunctiva has left the 
















Griffith_FINAL.indd   113 18/01/2016   14:54
114
Cataract and Cornea  
EUROPEAN OPHTHALMIC REVIEW
1. Oliva MS, Schottman T, Gulati M, Turning the tide of corneal 
blindness, Indian J Ophthalmol, 2012;60:423–7.
2. Lohiya S, Attal R, Bokariya P, Eye banking and corneal 
transplantation in tertiary care hospital located in rural area, 
IOSR J Pharmacy, 2014;4:11–6.
3. Eye Bank Association of America, 2013 Eye Banking Statistical 
Report. 2014: Washington, DC.
4. Eye Bank Association of America, 2009 Eye Banking Statistical 
Report. 2010: Washington, DC.
5. Mack RJ, Mason P, Mathers WD, Obstacles to donor eye 
procurement and their solutions at the University of Iowa, 
Cornea, 1995;14:249–52.
6. Poinard C, Tuppin P, Loty B, Delbosc B, The French national 
waiting list for keratoplasty created in 1999: patient 
registration, indications, characteristics, and turnover,  
J Fr Ophthalmol, 2003;26:911–9.
7. Rasouli M, Caraiscos VB, Slomovic AR, Efficacy of routine 
notification and request on reducing corneal transplantation 
wait times in Canada, Can J Ophthalmol, 2009;44:31–5.
8. Reinhard T, Bohringer D, Bogen A, Sundmacher R, The 
transplantation law: a chance to overcome the shortage of 
corneal grafts in Germany?, Transplant Proc, 2002;34:1322–4.
9. Avadhanam VS, Smith HE, Liu C, Keratoprostheses for  
corneal blindness: a review of contemporary devices,  
Clin Ophthalmol, 2015;9:697–720. 
10. Avadhanam VS, Liu CS, A brief review of Boston type-1 
and osteo-odonto keratoprostheses, Br J Ophthalmol, 
2015;99:878–87.
11. Guilbert E, Bullet J, Sandali O, et al., Long-term rejection 
incidence and reversibility after penetrating and lamellar 
keratoplasty, Am J Ophthalmol, 2013;155:560–9 e2.
12. Weisbrod DJ, Sit M, Naor J, Slomovic AR, Outcomes of repeat 
penetrating keratoplasty and risk factors for graft failure, 
Cornea, 2003;22:429–34.
13. Yu AL, Kaiser M, Schaumberger M, et al., Donor-related risk 
factors and preoperative recipient-related risk factors for 
graft failure, Cornea, 2014;33:1149–56.




corneenne/ (accessed 28 October 2015).
15. Klenkler BJ, Dwivedi D, West-Mays JA, Sheardown H, Corneal 
epithelial cell adhesion and growth on EGF-modified 
aminated PDMS, J Biomed Mater Res A, 2010;93:1043–9. 
16. Princz MA, Sheardown H, Heparin-modified dendrimer 
cross-linked collagen matrices for the delivery of basic 
fibroblast growth factor (FGF-2), J Biomater Sci Polym Ed, 
2008;19:1201–18. 
17. Aucoin L, Griffith CM, et al., Interactions of corneal epithelial 
cells and surfaces modified with cell adhesion peptide 
combinations, J Biomater Sci Polym Ed, 2002;13:447–62.
18. Liu L, Sheardown H, Glucose permeable poly (dimethyl 
siloxane) poly (N-isopropyl acrylamide) interpenetrating 
networks as ophthalmic biomaterials, Biomaterials, 
2005;26:233–44.
19. Proulx S, d’Arc Uwamaliya J, Carrier P, et al., Reconstruction 
of a human cornea by the self-assembly approach of tissue 
engineering using the three native cell types, Mol Vis, 
2010;16:2192–201.
20. Proulx S, Brunette I, Methods being developed for 
preparation, delivery and transplantation of a tissue-
engineered corneal endothelium, Exp Eye Res, 2012;95:68–75. 
21. Boulze Pankert M, Goyer B, Zaguia F, et al., Biocompatibility 
and functionality of a tissue-engineered living corneal stroma 
transplanted in the feline eye, Invest Ophthalmol Vis Sci, 
2014;55:6908–20. 
22. Fagerholm P, Lagali NS, Merrett K, et al., A biosynthetic 
alternative to human donor tissue for inducing corneal 
regeneration: 24-month follow-up of a phase 1 clinical study, 
Sci Transl Med, 2010;2:46ra61.
23. Fagerholm P, Lagali NS, Ong JA, et al., Stable corneal 
regeneration four years after implantation of a cell-free 
recombinant human collagen scaffold, Biomaterials, 
2014;35:2420–7.
24. Wand K, Neuhann R, Ullmann A, et al., Riboflavin-UV--a 
crosslinking for fixation of biosynthetic corneal collagen 
implants, Cornea, 2015;34:544–9.
25. Buznyk O, Pasyechnikova N, Islam MM, et al., Bioengineered 
corneas grafted as alternatives to human donor corneas in 
three high-risk patients, Clin Transl Sci, 2015;8:558–62. 
such as haze formation and surface irregularity after grafting of 
bioengineered collagen-based implants. 
Bioengineered Cornea Implants for  
High-risk Patients
The first RHCIII substitutes were implanted in non-inflamed corneas. 
In order to ensure that the next generation of implants will resist 
the insults of inflamed eyes, including collagenases, dryness and 
neovascularisation, which typically lead to ulceration, melting and 
opacification of the graft, the RHCIII implants were reinforced. A 
second network of 2-methacryloyloxyethyl phosphorylcholine (MPC) 
crosslinked with polyethylene (glycol) diacrylate (PEGDA) was added 
to form an interpenetrating network. The first RHCIII-MPC implants 
were developed in Canada, but optimisation for clinical evaluation 
was conducted in Sweden. The optimised generation of RHCIII-
MPC implants were tested in a pilot clinical study conducted in 
the Filatov Institute for Eye Diseases and Tissue Therapy, Odessa, 
Ukraine. Three patients with persistent ulceration and erosions of 
the cornea surface and who were at high risk of rejection of human 
donor corneas were implanted with RHCIII-MPC as tectonic grafts. 
All three patients showed relief of the symptoms of pain, irritation 
and photophobia. The implants were still stably integrated at 9 and 
12 months in the patients (see Figure 3). Two of three patients also 
showed improvement in vision.25 
Conclusion 
The field of cornea regeneration is one that is active and many groups are 
working on the development of new technologies. We have shown how 
several technologies developed by Canadian researchers have now been 
enhanced by ongoing European research including clinical evaluation. ■
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